Everolimus
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Everolimus and local guidelines before prescribing.
Mechanism
mTOR inhibitor.
Uses
Transplant rejection prophylaxis, renal cell carcinoma, breast cancer, tuberous sclerosis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Stomatitis, infections, hyperlipidaemia, pneumonitis, impaired wound healing.
Interactions
CYP3A4 and P-gp inhibitors and inducers alter levels.
Contraindications and cautions
Active infection
Monitoring
Levels, lipids, glucose, proteinuria
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in hepatic impairment
Overdose and reversal
Supportive
Special advice
Trough levels in transplantation; dental care for stomatitis.
More from the textbook: uses, cautions and other points
- Targeted drugs: Everolimus and sunitinib for progressive pancreatic NETs; everolimus for lung and GI NETs.
Endocrinology: NETS and Hypoglycaemia - Everolimus or PRRT for malignant insulinoma.
Endocrinology: NETS and Hypoglycaemia - Everolimus / sunitinib | Progressive pancreatic NETs (everolimus also lung and GI NETs).
Endocrinology: NETS and Hypoglycaemia - Tuberous sclerosis complex (TSC1 or TSC2) | Ash-leaf macules , facial angiofibromas , shagreen patch, nail fibromas; epilepsy (infantile spasms - vigabatrin), learning disability, autism; cortical tubers; renal angiomyolipomas ; cardiac rhabdomyomas (infancy); lung LAM in women. Everolimus (mTOR inhibitor)
Neurology: Spine and Sleep Disorders - Everolimus | Tuberous sclerosis complex (SEGA, angiomyolipoma, seizures).
Neurology: Spine and Sleep Disorders - mTOR inhibitors (sirolimus, everolimus) - poor wound healing, mouth ulcers, high lipids, proteinuria, pneumonitis.
Renal: Anatomy, Physiology and Pharmacology - Angiomyolipomas - can bleed (sudden loin pain and shock); everolimus or embolisation for large ones.
Renal: Tubular Inherited Stones - Sirolimus or everolimus (mTOR inhibitors) - poor wound healing, mouth ulcers, high lipids, proteinuria, pneumonitis; lower skin cancer risk.
Renal: Dialysis and Transplant
Where it is discussed in the book
- Endocrinology: NETS and Hypoglycaemia (3 mentions)
- Neurology: Spine and Sleep Disorders (2 mentions)
- Renal: Anatomy, Physiology and Pharmacology (1 mention)
- Renal: Tubular Inherited Stones (1 mention)
- Renal: Dialysis and Transplant (2 mentions)
- Oncology: Principles (1 mention)
- Oncology: Emergencies (1 mention)
- Oncology: Breast and Gynae Cancers (1 mention)
- Paediatrics: Neurology, bones and joints in children (1 mention)
- Dermatology: Skin lesions and skin cancer (1 mention)
- ID: Hospital infection, the immunocompromised host, vaccination and public health (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Clinical Genetics: Single-gene, repeat-expansion and mitochondrial disorders (1 mention)
- Integrated paediatrics chapter (1 mention)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)